# SymphonyRM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symphonyrm

- Industry: Software
- Headquarters: Palo Alto, US
- Website: www.symphonyrm.com
- Total disclosed funding: $35M
- Latest round: Series B (May 18, 2021)
- Investors on record: 2

## About

SymphonyRM Inc. develops an AI-powered patient communications platform that automates patient interactions, enhancing workflow efficiency in healthcare settings.Founded in 2014 and headquartered in Palo Alto, US, SymphonyRM Inc. specializes in patient engagement solutions. The company was founded by Michael Linnert, who has a background in the healthcare technology sector. SymphonyRM has completed 2 deals, with the most recent being a Series B funding round in May 2021, raising USD 25.00 mn led by TT Capital Partners and supported by Adams Street Partners. The total amount raised by the company is USD 25.00 mn.SymphonyRM offers a unique AI-powered patient communications platform that automates both inbound and outbound patient interactions. This solution streamlines workflows by managing routine inquiries through natural conversations, improving patient experiences. The platform addresses various healthcare needs, including automated scheduling, reminders, billing support, prescription refills, and preventative outreach, primarily serving hospitals and health systems.SymphonyRM generates revenue through an enterprise flat-fee pricing model, allowing clients predictable budgeting for its AI communications platform. This pricing typically involves annual subscriptions for healthcare organizations, enabling significant automation of patient communication processes, with reports indicating that up to 70% of routine calls can be managed by AI. Transactions occur between SymphonyRM and healthcare providers, integrating with existing systems for enhanced analytics and performance visibility.Following the Series B funding round in May 2021, SymphonyRM plans to utilize the USD 25.00 mn raised to enhance its sales and marketing efforts and expand its presence in the payer segment. The company is focused on targeting new markets and regions, although specific upcoming products and release dates have not been disclosed.

## Funding rounds

- Series B, May 18, 2021, $25M — Adams Street Partners, TT Capital Partners
- Series A, May 16, 2019, $10M — Adams Street Partners

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A, Series B
- TT Capital Partners — Series B